174 related articles for article (PubMed ID: 32468249)
1. Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma.
Kakimoto S; Miyamoto M; Einama T; Matsuura H; Iwahashi H; Ishibashi H; Sakamoto T; Hada T; Takano M
Pathol Oncol Res; 2020 Oct; 26(4):2299-2306. PubMed ID: 32468249
[TBL] [Abstract][Full Text] [Related]
2. Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis.
Kakimoto S; Miyamoto M; Einama T; Takihata Y; Matsuura H; Iwahashi H; Ishibashi H; Sakamoto T; Hada T; Suminokura J; Ito T; Suzuki R; Suzuki A; Takano M
Diagn Pathol; 2021 Apr; 16(1):28. PubMed ID: 33832498
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
4. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
5. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
6. Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels.
Devan SM; Pailoor J; Sthaneshwar P; Narayanan V
Asian Pac J Cancer Prev; 2013; 14(8):4545-8. PubMed ID: 24083699
[TBL] [Abstract][Full Text] [Related]
7. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
[TBL] [Abstract][Full Text] [Related]
8. Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses.
Manganaro L; Anastasi E; Porpora MG; Vinci V; Saldari M; Bernardo S; Ballesio L; Sollazzo P; Pecorella I; Recchia N; Stracci F; Panici PB; Angeloni A; Catalano C; Scialpi M
Anticancer Res; 2015 Nov; 35(11):6341-51. PubMed ID: 26504074
[TBL] [Abstract][Full Text] [Related]
9. Expression and clinical significance of Ki-67, E-cadherin, and mesothelin in serous borderline ovarian tumor.
Yu N; Wang N; Liu YF; Li YY; Zhang TG
Eur J Gynaecol Oncol; 2017; 38(1):85-90. PubMed ID: 29767871
[TBL] [Abstract][Full Text] [Related]
10. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
[TBL] [Abstract][Full Text] [Related]
11. Primary peritoneal serous papillary carcinoma: a clinical and pathological study.
Liu Q; Lin JX; Shi QL; Wu B; Ma HH; Sun GQ
Pathol Oncol Res; 2011 Sep; 17(3):713-9. PubMed ID: 21647781
[TBL] [Abstract][Full Text] [Related]
12. Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma.
Orsaria M; Londero AP; Marzinotto S; Di Loreto C; Marchesoni D; Mariuzzi L
Cancer Biomark; 2016; 17(4):479-486. PubMed ID: 27802199
[TBL] [Abstract][Full Text] [Related]
13. High expression of mesothelin in advanced serous ovarian cancer is associated with poor prognosis.
Yildiz Y; Kabadayi G; Yigit S; Kucukzeybek Y; Alacacioglu A; Varol U; Taskaynatan H; Salman T; Oflazoglu U; Akyol M; Tarhan MO
J BUON; 2019; 24(4):1549-1554. PubMed ID: 31646807
[TBL] [Abstract][Full Text] [Related]
14. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
15. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
[TBL] [Abstract][Full Text] [Related]
16. Expression of estrogen-related receptors in ovarian cancer and impact on survival.
Schüler-Toprak S; Weber F; Skrzypczak M; Ortmann O; Treeck O
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2555-2567. PubMed ID: 34089362
[TBL] [Abstract][Full Text] [Related]
17. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
18. The frequency and significance of WT-1 expression in serous endometrial carcinoma.
Hedley C; Sriraksa R; Showeil R; Van Noorden S; El-Bahrawy M
Hum Pathol; 2014 Sep; 45(9):1879-84. PubMed ID: 25033726
[TBL] [Abstract][Full Text] [Related]
19. Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer.
Aktas B; Kasimir-Bauer S; Wimberger P; Kimmig R; Heubner M
Anticancer Res; 2013 Jan; 33(1):329-36. PubMed ID: 23267165
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer.
May T; Stewart JM; Bernardini MQ; Ferguson SE; Laframboise S; Jiang H; Rosen B
Int J Gynaecol Obstet; 2018 Feb; 140(2):247-252. PubMed ID: 29095487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
